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Purpose: To assess the effects of oral vitamin D supplement therapy on clinical outcomes of
intravitreal bevacizumab (IVB) injections in patients with diabetic macular edema (DME).
Method: Seventy-one patients with center-involving DME received IVB injections three times
monthly. Cases with serum 25-hydroxyvitamin D (25(OH)D) levels <30 ng/ml were divided into
treatment and control groups. The treatment group received 50000 IU of oral vitamin D once
a week for eight weeks. One month after the third IVB injection, changes in the best-corrected
visual acuity (BCVA) and central macular thickness (CMT) were analyzed for each group.
Results: Thirty-seven patients had sufficient levels of 25 (OH) D, while 34 patients had insufficient
levels. Nineteen cases with deficient levels of 25(OH)D were treated with oral vitamin D, while 15
patients were assigned to the control group. The mean of serum 25(OH)D in patients was 27.9
ng/ml [mean 20.3 ± 5.4 and 17.3 ± 5.4 ng/ml in control and treatment groups, respectively (P =
0.231)]. After three IVB injections, BCVA improved significantly in each group, but the difference
between the study groups was not statistically significant. CMT decreased significantly in all the
groups. The mean CMT reduction was more prominent in the vitamin D-treated group, but the
difference between groups did not reach statistical significance (P = 0.29).
Conclusion: In DME patients with vitamin D deficiency, vitamin D supplement therapy had some
beneficial effects on CMT reduction following three injections of IVB; nevertheless, these effects
were not statistically significant. Definite conclusion needs further prospective studies with a
larger sample size.
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Diabetic macular edema (DME) may develop
in diabetic patients, independent of the severity
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of diabetic retinopathy (DR).[1] DME is the main
cause of decreased vision in diabetic patients.[1]
Elevated levels of various inflammatory and
angiogenic factors lead to serious damage
of retinal vascular endothelial cells, and the
consequent impairment of blood–retinal barrier
(BRB) causes fluid accumulation in the retinal
tissue.[2]
Vitamin D is a well-known endocrine
secosteroid which plays an essential role in
many physiologic processes, including the control
of cellular apoptosis and differentiation, as well as
angiogenesis and metastasis potential of human
cancer cells.[3–6] Various cardiovascular, infectious,
and autoimmune diseases have been revealed to
be linked with vitamin D deficiency.[7]
Both the vitamin D activator enzyme (1-α-
hydroxylase ) and its receptor have been found in
the retina,[8, 9] suggesting that 25(OH)D abnormal
levels may participate in the development and
progression of various retinal disorders, including
DR. Deficient serum 25(OH)D levels have been
shown to be correlated with more advanced DR
and its vision-threatening outcomes.[10, 11]
In this study, we measured the serum vitamin D
levels in patients scheduled to receive intravitreal
bevacizumab (IVB) for DME. We investigated the
influence of oral vitamin D supplement therapy on
the outcomes of IVB injections in these patients.
METHODS
The current prospective comparative case series
study was carried out between March 2017 and
August 2018. The protocol was approved by the
Ethics Committee of the Ophthalmic Research
Center at the Shahid Beheshti University of Medical
Sciences and followed the Declaration of Helsinki.
A written consent was obtained from all patients.
One eye from each patient was enrolled in
the study. A diagnosis of center-involving DME
was made if the central macular thickness (CMT)
(within central 1-mm of macula) was >300 μm
on optical coherence tomography (OCT) image
(Spectralis OCT; Heidelberg Engineering, Vista,
CA). Subjects were eligible for enrolment if BCVA
was between 20/40 and 20/320 according to the
Snellen chart in the eye enrolled in the study.
The exclusion criteria were history of intravitreal
anti-VEGF injections in the last three months of
enrolment, history of intraocular surgery other
than uncomplicated cataract surgery, patients
with proliferative DR, retinal vascular occlusions,
glaucoma, a creatinine (Cr) level > 3 mg/dl,
thyroid and parathyroid diseases, liver disease
or any other problem of vitamin D absorption,
recent use of supplements containing vitamin D
or 25(OH)D, use of medications with known effect
on serum 25(OH)D levels such as anticonvulsants
and corticosteroids, and serum 25(OH)D level ≤ 10
ng/ml.
All patients were scheduled to receive
IVB (Avastin®, Genentech/Roche, CA, USA)
three times monthly. All subjects underwent
intravitreal injections at the Torfeh Eye Hospital.
Ophthalmologists who performed the injections
were masked to the groups. The study was
performed during a single season to avoid
variations in serum vitamin D levels due to
seasonal exposures.
Before enrolment, all patients underwent
complete ophthalmic examination. Parameters
including age, sex, BCVA, and CMT were
measured for each subject. On the day of first
injection, venous blood specimen was analyzed
for 25(OH)D, Cr, and HbA1c levels. Patients with
>30 ng/ml of 25-hydroxyvitamin D (25(OH)D) were
considered as vitamin D-sufficient group. Patients
with <30 ng/ml were enrolled in the control group.
The subjects were assigned to treatment groups on
a random basis without considering the 25(OH)D
levels. Thus, we had three study groups: group
1 (vitamin D-sufficient group with serum vitamin
D ≥ 30 ng/ml), group 2 (vitamin D-deficiency
group treated with oral vitamin D supplement),
and group 3 (vitamin D-deficiency control group).
The treatment group received a pearl of vitamin
D3 (D-Vigel 50000 IU, Daana Pharmaceutical
Company, Iran) once a week for eight consecutive
weeks during the first two months of the IVB
treatment period. Fundus examination and OCT
imaging were repeated before any procedure.
Visual acuity measurements were obtained
through Snellen chart examination by a trained
optometrist who was masked as to which group
the patients were assigned to, and were converted
to LogMAR values. Severity of DR was determined
by a single ophthalmologist using three field
fundus photographs (optic disc centered, fovea
centered, and centered on temporal edge of
the macula), and was categorized according to
the International DR Severity Scale.[12] Ophthalmic
evaluations were repeated one month after the
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third intravitreal injection. The mean changes in
BCVA and CMT from baseline to one month
after the third injection were measured as primary
and secondary outcomes, respectively. After the
completion of the study protocol, patients of the
control group were also treated with oral vitamin D
supplement.
To present data, mean and standard deviation
were used. T-test was used for comparing serum
vitamin D and HbA1c between the groups, and the
correlation between HbA1c and vitamin D levels
was evaluated by linear regression analysis. To
evaluate the role of treatment on LogMAR and
CMT changes, paired t-test analysis was used. The
differences were considered as significant if p-
value was < 0.05 (Figure 1). Finally, to determine
the adequacy of the sample size and the power of
the study, a post-hoc analysis was performed.
RESULTS
Eighty-three patients participated in the study.
Four patients were excluded due to urgent need
for supplement therapy (vitamin D level < 10
ng/ml). Eight patients (one patient from treatment
group, five patients from control group, and two
patients from sufficient group) did not complete
the study. Out of the 71 subjects analyzed at
the end of study, 37 patients had sufficient
levels of 25(OH)D, 19 had insufficient 25(OH)D
and were treated with oral vitamin D supplement
(treatment group), and 15 cases with insufficient
25(OH)D levels were enrolled as the control
group. Demographic characteristics and baseline
parameters are summarized in Table 1. The study
groups were matched in terms of age, sex, and
severity of DR (Table 1).
The average HbA1c levels in the sufficient
(n = 37) and the insufficient (n = 34) groups
were 7.3% and 8.2%, respectively (P < 0.05,
Figure 1a). The difference of HbA1c levels between
the treatment and the control groups was not
statistically significant (P > 0.05, 95% CI).
The mean serum 25(OH)D level was 27.9 ng/ml
and it did not show any statistical correlation with
patients’ sex (P = 0.653). Regression analysis
showed that serum 25(OH)D levels had negative
correlation with the HbA1c levels (Pearson’s
correlation coefficient = –0.032) in all the patients.
The P-value for the correlation was 0.007, showing
a significant relationship (Figure 2).
The mean levels of serum 25(OH)D were 36.5 ±
6.7, 17.3 ± 5.4, and 20.3 ± 5.4 ng/ml in the sufficient
group, the insufficient treatment group, and the
insufficient control group, respectively (Figure 1b).
The mean 25(OH)D level was significantly higher in
the sufficient group, while the difference between
the control and the treatment groups was not
statistically significant (P = 0.231, 95% CI) (Table 1).
The mean BCVA values at the baseline
were 0.51 ± 0.28, 0.48 ± 0.32, and 0.58 ± 0.25
LogMAR in the sufficient group, the insufficient
treatment group, and the insufficient control group,
respectively (P > 0.05, 95% CI). One month after
the third IVB injection, BCVA improved significantly
in all the study groups. The mean changes in BCVA
were –0.13 ± 0.12, –0.15 ± 0.11, and –0.16 ± 0.17
LogMAR in the sufficient group, the insufficient
treatment group, and the insufficient control group,
respectively (P = 0.66). The mean changes in BCVA
were not significantly different between the study
groups (Table 2 and Figure 3a).
The mean CMT values were 517 ± 112 µm, 514 ±
105 µm, and 509±74 µm in the sufficient group, the
insufficient treatment group, and the insufficient
control group, respectively (P = 0.97, 95% CI). One
month after the third IVB injection, the mean CMT
decreased significantly in all the study groups. The
mean CMT changes were –100± 97, –131± 67, and
–91 ± 53 µm in the sufficient group, the insufficient
treatment group, and the insufficient control group,
respectively (P = 0.29). Although the mean CMT
decreased more in patients who received oral
vitamin D supplement (–131 µm vs –100 µm and –91
µm), the difference was not statistically significant
(P = 0.29, Table 2 and Figure 3b).
Post-hoc analysis showed that the sample size
should be 41 in each group to find a significant
difference (50 microns) in the changes of CMT to
achieve the study power of 95%. However, the
present study had a power of 60%. Endophthalmitis
or significant ocular or systemic complications
were not observed.
DISCUSSION
We observed that vitamin D supplement therapy
in the subset of diabetic patients with DME and
insufficient levels of vitamin D could not improve
the outcome of IVB therapy. According to our
knowledge, this study was the first to investigate
the effect of oral vitamin D supplement therapy on
clinical outcomes of IVB injection in DME.
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Figure 1. The mean HbA1c (a) and vitamin D levels (b) in different study groups.
Figure 2. The correlation chart of vitamin D and HbA1c levels.
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Figure 3. Changes in visual acuity (a) and central retinal thickness (b) following IVB therapy. CMT, central macular thickness;
LogMAR, logarithm of minimal angel resolution; IVB, intravitreal bevacizumab
There is still a degree of uncertainty about
the influence of serum vitamin D in occurrence,
progression, and prognosis of DR. The controversy
begins from the concept that serum vitamin D
deficiency may not be correlated with a concurrent
ocular deprivation. It is believed that the eye can
produce vitamin D through exposure to ultraviolet
light, and the BRB can limit the transmission of
vitamin D from blood to the eyes.[13, 14] Accordingly,
some authors have suggested that intraocular
25(OH)D levels may not depend on systemic
25(OH)D levels.[1]
It has also been reported that the 1,25-
dihydroxycholecalciferol can upregulate the
expression of the VEGFs; it has been shown that
the regulation of VEGF promoter by vitamin D
receptor increases the secretion of VEGFs in
vascular smooth muscles.[15, 16] A similar effect has
not been established in retinal cells, however,
this finding can hypothesize a correlation between
high ocular vitamin D levels and high concentration
of ocular VEGFs.[1]
Previous studies have revealed paradoxical
results about the relationship between the
severity of DR and serum 25(OH)D levels.
Some authors have reported an inverse
relationship,[10, 11, 17–19] while others have not shown
such a correlation.[20, 21] A meta-analysis on the
topic reported that those patients with DM type 2
and vitamin D deficiency have a higher risk of DR
development compared to subjects with adequate
levels of the vitamin.[22] On the other hand, a recent
study performed by Kim et al reported that patients
with DME had a greater aqueous humor amounts
of vitamin D than the patients without DME.[1] It
should also be considered that studies on vitamin
D levels encounter some challenges such as
different cultural backgrounds as well as different
38 JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 16, ISSUE 1, JANUARY-MARCH 2021
Effects of Vitamin D on the IVB Injection Outcomes; Karimi et al
Table 1. Demographic and clinical features









Age Mean ± SD 63 ± 8 65 ± 6 59 ± 8 64 ± 9 62 ± 9 0.076
Median (range) 64 (40,84) 64 (52,84) 59 (45,74) 64 (40,84) 63 (40,84)
Sex Male 37 (52.1%) 18 (48.6%) 7 (46.7%) 12 (63.2%) 19 (55.9%) 0.518
Female 34 (47.9%) 19 (51.4%) 8 (53.3%) 7 (36.8%) 15 (44.1%)
Eye OD 37 (52.1%) 22 (59.5%) 5 (33.3%) 10 (52.6%) 15 (44.1%) 0.252
OS 34 (47.9%) 15 (40.5%) 10 (66.7%) 9 (47.4%) 19 (55.9%)
DR NPDR 32 (45.1%) 19 (51.4%) 5 (33.3%) 8 (42.1%) 13 (38.2%) 0.511
PDR 39 (54.9%) 18 (48.6%) 10 (66.7%) 11 (57.9%) 21 (61.8%)
HbA1c Mean ± SD 7.7 ± 1.5 7.3 ± 1.6 7.9 ± 1.3 8.3 ± 1.1 8.2 ± 1.2 0.043
Median (range) 7.6 (4.9,10.7) 6.7 (4.9,10.7) 8.2 (6.1,9.6) 8.1 (6.7,10.4) 8.1 (6.1,10.4)
Vitamin D (μg) Mean ± SD 27.9 ± 10.8 36.5 ± 6.7 20.3 ± 5 17.3 ± 5.4 18.6 ± 5.4 <0.001
Median (range) 31 (5,66.3) 34.2 (31,66.3) 22 (10,26.2) 18 (5,27) 19.5 (5,27)
DR, diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; OD, right eye; OS, left eye; PDR, proliferative diabetic
retinopathy; HbA1c, hemoglobin A1c; SD, standard deviation
Table 2. Best-corrected visual acuity changes after three intravitreal bevacizumab injections
BCVA (LogMAR) Total Groups P-value
Sufficient Insufficient-control Insufficient-treatment
Baseline 0.51 ± 0.28 0.5 ± 0.28 0.58 ± 0.25 0.48 ± 0.32 0.587
Final F/U 0.37 ± 0.24 0.38 ± 0.24 0.42 ± 0.24 0.33 ± 0.23 0.554
Change –0.14 ± 0.13 –0.13 ± 0.12 –0.16 ± 0.17 –0.15 ± 0.11 0.659
P-value <0.001 0.002 <0.001
CMT (µm)
Baseline 514 ± 102 517 ± 112 509 ± 74 514 ± 105 0.97
Final F/U 408 ± 96 417 ± 111 417 ± 61 383 ± 87 0.42
Change –106± 83 –100± 97 –91± 53 –131± 68 0.29
P-value <0.001 <0.001 <0.001
BCVA, best-corrected visual acuity; F/U, follow-up; CMT, central macular thickness
clothing and diet styles. Vitamin D in the body can
be supplied both from dietary sources and from
synthesis in the skin. Accordingly, it is difficult to
control the dietary, environmental, seasonal, and
cultural factors, in addition to predict serum vitamin
D levels through single measurement, which can
cause inconclusive results.
Since the prior studies have not resulted in
an exact conclusion about vitamin D and its role
in DR, we investigated the treatment of DME
with an anti-VEGF agent, bevacizumab, in the
presence of vitamin D deficiency. We also tested
the role of concurrent vitamin D3 therapy in
optimizing the IVB therapy for DME. We found
that the concurrent vitamin D supplement therapy
in this subset of patients did not significantly
improve the outcomes of IVB in DME cases with
vitamin D deficiency. Although improvement in
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BCVA and decrease in CMT was more prominent
in the treatment group, the difference between
the control and the treatment groups was not
statistically significant. Future studies on larger
group of patients may reveal an association
between vitamin D supplementation and improved
outcomes of IVB injections in DME patients.
We found a negative correlation between HbA1c
levels and serum 25(OH)D, implying that patients
with 25(OH)D deficiency had a higher rate of
uncontrolled hyperglycemia. This finding may be
in accordance with prior reports regarding the
correlation of vitamin D deficiency with poor
glycemic control and DR severity.[22] It has been
postulated that vitamin D may improve insulin
secretion, stimulate insulin receptor, and improve
glucose uptake in type 2 diabetes.[9, 23] According
to these assumptions, vitamin D may improve
insulin resistance. However, it should be proven in
experimental studies.
A small sample size in addition to the lack of a
control for those habits and restrictions which may
affect vitamin D storage in the body are the main
limitations of the present study. Although vitamin D
deficiency was treated according to the standard
protocol, effectiveness of vitamin D supplement
therapy was not assessed at the end of the study.
Short-term follow-up could also be considered as
another limitation of the present study; however,
longer follow-upwas not possible due to the ethical
issues.
In conclusion, we observed a negative
correlation between HbA1c and 25(OH)D levels.
Although vitamin D supplement therapy, added to
IVB therapy, had some beneficial effects in terms
of CMT reduction in DME patients with 25(OH)D
deficiency, we could not find any statistically
significant effect of the adjunctive therapy on
the functional and anatomical outcomes of these
patients. Further studies are required to investigate
the effect of D3 supplement therapy on optimizing
the treatment of patients with DR.
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